title: Reply to L. Del Mastro and A. Prat.
authors.affiliation: Neelima Denduluri, Virginia Cancer Specialists, US Oncology Network, Arlington, VA; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; Andrea Eisen, Sunnybrook Odette Cancer Centre, and Cancer Care Ontario, Toronto, Canada; Jamie N. Holloway, Arlington, VA; Arti Hurria, City of Hope, Duarte, CA; Tari A. King, Dana-Farber Cancer Institute, and Brigham & Women's Cancer Center; Boston, MA; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Melinda L. Telli, Stanford University, Palo Alto, CA; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, and Cancer Care Ontario, Toronto, Canada; and Antonio C. Wolff, Johns Hopkins Kimmel Cancer Center, Baltimore, MD.
authors.forename: Neelima
authors.initials: N
authors.lastname: Denduluri
authors.affiliation: Neelima Denduluri, Virginia Cancer Specialists, US Oncology Network, Arlington, VA; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; Andrea Eisen, Sunnybrook Odette Cancer Centre, and Cancer Care Ontario, Toronto, Canada; Jamie N. Holloway, Arlington, VA; Arti Hurria, City of Hope, Duarte, CA; Tari A. King, Dana-Farber Cancer Institute, and Brigham & Women's Cancer Center; Boston, MA; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Melinda L. Telli, Stanford University, Palo Alto, CA; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, and Cancer Care Ontario, Toronto, Canada; and Antonio C. Wolff, Johns Hopkins Kimmel Cancer Center, Baltimore, MD.
authors.forename: Mark R
authors.initials: MR
authors.lastname: Somerfield
authors.affiliation: Neelima Denduluri, Virginia Cancer Specialists, US Oncology Network, Arlington, VA; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; Andrea Eisen, Sunnybrook Odette Cancer Centre, and Cancer Care Ontario, Toronto, Canada; Jamie N. Holloway, Arlington, VA; Arti Hurria, City of Hope, Duarte, CA; Tari A. King, Dana-Farber Cancer Institute, and Brigham & Women's Cancer Center; Boston, MA; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Melinda L. Telli, Stanford University, Palo Alto, CA; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, and Cancer Care Ontario, Toronto, Canada; and Antonio C. Wolff, Johns Hopkins Kimmel Cancer Center, Baltimore, MD.
authors.forename: Andrea
authors.initials: A
authors.lastname: Eisen
authors.affiliation: Neelima Denduluri, Virginia Cancer Specialists, US Oncology Network, Arlington, VA; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; Andrea Eisen, Sunnybrook Odette Cancer Centre, and Cancer Care Ontario, Toronto, Canada; Jamie N. Holloway, Arlington, VA; Arti Hurria, City of Hope, Duarte, CA; Tari A. King, Dana-Farber Cancer Institute, and Brigham & Women's Cancer Center; Boston, MA; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Melinda L. Telli, Stanford University, Palo Alto, CA; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, and Cancer Care Ontario, Toronto, Canada; and Antonio C. Wolff, Johns Hopkins Kimmel Cancer Center, Baltimore, MD.
authors.forename: Jamie N
authors.initials: JN
authors.lastname: Holloway
authors.affiliation: Neelima Denduluri, Virginia Cancer Specialists, US Oncology Network, Arlington, VA; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; Andrea Eisen, Sunnybrook Odette Cancer Centre, and Cancer Care Ontario, Toronto, Canada; Jamie N. Holloway, Arlington, VA; Arti Hurria, City of Hope, Duarte, CA; Tari A. King, Dana-Farber Cancer Institute, and Brigham & Women's Cancer Center; Boston, MA; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Melinda L. Telli, Stanford University, Palo Alto, CA; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, and Cancer Care Ontario, Toronto, Canada; and Antonio C. Wolff, Johns Hopkins Kimmel Cancer Center, Baltimore, MD.
authors.forename: Arti
authors.initials: A
authors.lastname: Hurria
authors.affiliation: Neelima Denduluri, Virginia Cancer Specialists, US Oncology Network, Arlington, VA; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; Andrea Eisen, Sunnybrook Odette Cancer Centre, and Cancer Care Ontario, Toronto, Canada; Jamie N. Holloway, Arlington, VA; Arti Hurria, City of Hope, Duarte, CA; Tari A. King, Dana-Farber Cancer Institute, and Brigham & Women's Cancer Center; Boston, MA; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Melinda L. Telli, Stanford University, Palo Alto, CA; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, and Cancer Care Ontario, Toronto, Canada; and Antonio C. Wolff, Johns Hopkins Kimmel Cancer Center, Baltimore, MD.
authors.forename: Tari A
authors.initials: TA
authors.lastname: King
authors.affiliation: Neelima Denduluri, Virginia Cancer Specialists, US Oncology Network, Arlington, VA; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; Andrea Eisen, Sunnybrook Odette Cancer Centre, and Cancer Care Ontario, Toronto, Canada; Jamie N. Holloway, Arlington, VA; Arti Hurria, City of Hope, Duarte, CA; Tari A. King, Dana-Farber Cancer Institute, and Brigham & Women's Cancer Center; Boston, MA; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Melinda L. Telli, Stanford University, Palo Alto, CA; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, and Cancer Care Ontario, Toronto, Canada; and Antonio C. Wolff, Johns Hopkins Kimmel Cancer Center, Baltimore, MD.
authors.forename: Gary H
authors.initials: GH
authors.lastname: Lyman
authors.affiliation: Neelima Denduluri, Virginia Cancer Specialists, US Oncology Network, Arlington, VA; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; Andrea Eisen, Sunnybrook Odette Cancer Centre, and Cancer Care Ontario, Toronto, Canada; Jamie N. Holloway, Arlington, VA; Arti Hurria, City of Hope, Duarte, CA; Tari A. King, Dana-Farber Cancer Institute, and Brigham & Women's Cancer Center; Boston, MA; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Melinda L. Telli, Stanford University, Palo Alto, CA; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, and Cancer Care Ontario, Toronto, Canada; and Antonio C. Wolff, Johns Hopkins Kimmel Cancer Center, Baltimore, MD.
authors.forename: Ann H
authors.initials: AH
authors.lastname: Partridge
authors.affiliation: Neelima Denduluri, Virginia Cancer Specialists, US Oncology Network, Arlington, VA; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; Andrea Eisen, Sunnybrook Odette Cancer Centre, and Cancer Care Ontario, Toronto, Canada; Jamie N. Holloway, Arlington, VA; Arti Hurria, City of Hope, Duarte, CA; Tari A. King, Dana-Farber Cancer Institute, and Brigham & Women's Cancer Center; Boston, MA; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Melinda L. Telli, Stanford University, Palo Alto, CA; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, and Cancer Care Ontario, Toronto, Canada; and Antonio C. Wolff, Johns Hopkins Kimmel Cancer Center, Baltimore, MD.
authors.forename: Melinda L
authors.initials: ML
authors.lastname: Telli
authors.affiliation: Neelima Denduluri, Virginia Cancer Specialists, US Oncology Network, Arlington, VA; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; Andrea Eisen, Sunnybrook Odette Cancer Centre, and Cancer Care Ontario, Toronto, Canada; Jamie N. Holloway, Arlington, VA; Arti Hurria, City of Hope, Duarte, CA; Tari A. King, Dana-Farber Cancer Institute, and Brigham & Women's Cancer Center; Boston, MA; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Melinda L. Telli, Stanford University, Palo Alto, CA; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, and Cancer Care Ontario, Toronto, Canada; and Antonio C. Wolff, Johns Hopkins Kimmel Cancer Center, Baltimore, MD.
authors.forename: Maureen E
authors.initials: ME
authors.lastname: Trudeau
authors.affiliation: Neelima Denduluri, Virginia Cancer Specialists, US Oncology Network, Arlington, VA; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; Andrea Eisen, Sunnybrook Odette Cancer Centre, and Cancer Care Ontario, Toronto, Canada; Jamie N. Holloway, Arlington, VA; Arti Hurria, City of Hope, Duarte, CA; Tari A. King, Dana-Farber Cancer Institute, and Brigham & Women's Cancer Center; Boston, MA; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Melinda L. Telli, Stanford University, Palo Alto, CA; Maureen E. Trudeau, Sunnybrook Health Sciences Centre, and Cancer Care Ontario, Toronto, Canada; and Antonio C. Wolff, Johns Hopkins Kimmel Cancer Center, Baltimore, MD.
authors.forename: Antonio C
authors.initials: AC
authors.lastname: Wolff
mesh_terms: D001943:Breast Neoplasms; D017024:Chemotherapy, Adjuvant; D006801:Humans